Sign up to save your podcasts
Or
Share Triple Negative Breast Cancer (TNBC) Treatment Algorithm: Dr. Tiffany Traina
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Triple Negative Breast Cancer (TNBC) Treatment Algorithm: Dr. Tiffany Traina
Welcome to the Oncology Brothers podcast! In this episode we continue our series on breast cancer treatment algorithms, focusing specifically on triple negative breast cancer (TNBC). We welcomed Dr. Tiffany Traina, a breast medical oncologist from the Memorial Sloan Kettering Cancer Center, to discuss the latest advancements in the management of TNBC. We dived deep into the treatment algorithm for early-stage disease, including the criteria for adjuvant chemotherapy, the use of neoadjuvant therapies like KEYNOTE-522, and the importance of balancing risk and benefit in treatment decisions.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Key topics covered in this episode included:
* Criteria for adjuvant chemotherapy in early-stage TNBC
* The role of pembrolizumab in neoadjuvant and adjuvant settings
* Management of residual disease with capecitabine and olaparib
* Insights into the latest clinical trials, including ASCENT-03, ASCENT-04, and TROPION-Breast02
* Side effect management strategies for new therapies
Don't forget to subscribe for more episodes in our breast cancer series, and feel free to send us your questions and cases!
Listen now and stay informed on the evolving landscape of triple negative breast cancer treatment!
#TripleNegativeBreastCancer, #TNBC, #Pembrolizumab, #ADC, #OncologyBrothers
View all episodes
By Oncology Brothers
4.9
4242 ratings
Welcome to the Oncology Brothers podcast! In this episode we continue our series on breast cancer treatment algorithms, focusing specifically on triple negative breast cancer (TNBC). We welcomed Dr. Tiffany Traina, a breast medical oncologist from the Memorial Sloan Kettering Cancer Center, to discuss the latest advancements in the management of TNBC. We dived deep into the treatment algorithm for early-stage disease, including the criteria for adjuvant chemotherapy, the use of neoadjuvant therapies like KEYNOTE-522, and the importance of balancing risk and benefit in treatment decisions.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Key topics covered in this episode included:
* Criteria for adjuvant chemotherapy in early-stage TNBC
* The role of pembrolizumab in neoadjuvant and adjuvant settings
* Management of residual disease with capecitabine and olaparib
* Insights into the latest clinical trials, including ASCENT-03, ASCENT-04, and TROPION-Breast02
* Side effect management strategies for new therapies
Don't forget to subscribe for more episodes in our breast cancer series, and feel free to send us your questions and cases!
Listen now and stay informed on the evolving landscape of triple negative breast cancer treatment!
#TripleNegativeBreastCancer, #TNBC, #Pembrolizumab, #ADC, #OncologyBrothers
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
122 Listeners
ASCO Daily News
59 Listeners
Pod Save America
88,021 Listeners
Core IM | Internal Medicine Podcast
1,141 Listeners
The ONS Podcast
203 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
47 Listeners
OncLive® On Air
23 Listeners
Lung Cancer Considered
27 Listeners
Oncology Today with Dr Neil Love
61 Listeners
Oncology On The Go
4 Listeners
Blood Cancer Talks
51 Listeners
Two Onc Docs
196 Listeners
Oncology for the Inquisitive Mind
4 Listeners